Lupus can cause a wide range of symptoms that are easy to mistake for other conditions. This video explores common warning ...

Preliminary results from an investigator-initiated, single-site clinical study show that some people with chronic cutaneous ...

Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ...

We are joined by experts who share practical strategies for navigating daily life with lupus, address the emotional side of the disease, and provide tools to help you cope, build confidence, and take ...

Beginning in September, the Lupus Foundation of America's 2026 Walk to End Lupus Now events will unite people with lupus, ...

If envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach the ...

Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage ...

Neuropsychiatric symptoms are common in systemic lupus erythematosus (SLE), typically featuring impaired cognition and ...

Fate Therapeutics starts Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, with Phase 1 promise and pipeline updates.

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Objective This study aimed to compare 25-hydroxyvitamin D (25-(OH)D) levels and peripheral lymphocyte subsets between ...

Sept 1 (Reuters) - Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet ...